PumpsResearch of Type 1 Diabetes

Tandem Scores Big With Artificial Pancreas Research

There are times when it’s not easy being a spokesperson, like when you have to stand at a podium and neither confirm nor deny the latest political scandal. And then there are times when being a spokesman is more fun, like when the insulin pump company you represent was just involved in successful trials of a closed-loop artificial pancreas system.

Steve Sabicer is experiencing the latter as spokesman for Tandem, the relatively new insulin pump company on the block. Just a few years after hitting the market with its t:slim, the company is basking in the glow of major news cycle success, as the t:slim was involved in the recent Boston University/Massachusetts General Hospital trials of an artificial pancreas system that made mainstream news.

In the experiment, two t:slims were hooked up to patients in the experimental groups, one to pump insulin and another to pump glucagon. They were then wired, using t:slim’s bluetooth technology, to talk to a Dexcom continuous glucose monitor (CGM) to adjust levels automatically. The system, controlled by modified iPhones, did a superb job controlling blood glucose levels in patients and preventing bouts of hypoglycemia, researchers reported.

Tandem has had to break into a pump market dominated by Medtronic and Johnson & Johnson, and its success in artificial pancreas trials has provided a real boost. Researchers select the t:slim for its bluetooth capability, says Sabicer. They also like the pump’s small design and touchscreen interface. He estimates that t:slim pumps are being used in about a half-dozen artificial pancreas trials across the country.

”Considering that the company has only been around for a couple of years, that’s an amazing number,” Sabicer says.

It probably was especially sweet for Tandem that their pumps were involved in dual-hormone artificial pancreas trials (some trials only focus on automating insulin delivery). Tandem has long been focused on the concept of two-hormone pump therapy, and wants its pumps to be “hormone agnostic,” says Sabicer. In 2013, the company signed a partnership with the Juvenile Diabetes Research Foundation (JDRF) to develop what is being dubbed the “t:dual”, a pump that can deliver insulin and another drug hormone. Glucagon would be the obvious candidate, but the company is also hoping the t:dual can eventually be cleared to pump other drugs, like the blood-sugar-regulating pramlintide (aka Symlin).

The Boston University and Mass General Hospital trials showed that the Tandem pumps are capable of handling a second hormone, Sabicer says. Unfortunately, drug companies haven’t yet figured out a way to create FDA-approved room-temperature-stable glucagon. In the BU/MGH trials, researchers often had to replace the glucagon being used, he says.

“The mechanics of the pump are not necessarily the limiting factor,” Sabicer says.

(Drug manufacturer Xeris is currently testing its attempt at room-temperature-stable glucagon in trials with OmniPod pumps. To learn more about that, read “Is Glucagon Ready for Primetime?”)

In the short term, Tandem will be focusing on the other strengths of the t:slim pump design, including the bluetooth technology embedded in the t:slim and the pump’s slim design. Tandem hopes to convince the FDA to allow the company to turn on the bluetooth technology, so the t:slim can talk to a Dexcom CGM in an integrated system (currently, only Medtronic has won regulatory approval in Europe for an integrated pump and CGM system, the Duo). Tandem also is working towards adding a larger insulin chamber to its pump.

As Tandem now has become a publically-traded company, Sabicer said firm timelines for next steps will be given at quarterly earnings report conference calls. The next call is scheduled for July 31st, 2014. By then, Sabicer might have even more good news to share about his company’s progress.

Thanks for reading this Insulin Nation article. Want more Type 1 news? Subscribe here.

Have Type 2 diabetes or know someone who does? Try Type 2 Nation, our sister publication.

Craig Idlebrook is a past editor for Insulin Nation, Type 2 Nation, and Información Sobre Diabetes. He is now the community engagement and content manager for T1D Exchange.

Related Articles


  1. “Thanks for the sensible critique. Me & my neighbor were just preparing to do some research about this. We got a grab a book from our local library but I think I learned more from this post. I’m very glad to see such fantastic info being shared freely out there.”

  2. ygctfqrgq,Thanks for ones marvelous posting! I actually enjoyed reading it, you will be a great author.I will always bookmark your blog and will cnlsukomhwm,come back from now on. I want to encourage that you continue your great writing, have a nice afternoon!

  3. rwoixbw,Very informative useful, infect very precise and to the point. Im a student a Business Education and surfing things on Google and found your website and found it very informative.

  4. iextvapygd,Are you searching for top class Escort service in Noida and want to enjoy with them, hire sexy girls from top Greater Noida escort service and enjoy full night.

  5. rigikhvrizv,Thanks a lot for providing us with this recipe of Cranberry Brisket. I’ve been wanting to make this for a long time but I couldn’t find the right recipe. Thanks to your help here, I can now make this dish easily.

  6. That is a very good tip especially to those fresh to the blogosphere. Short but very precise information… Appreciate your sharing this one. A must read post!

  7. slvfntwsoi,A fascinating discussion is definitely worth comment. I do think that you ought to publish more on this topic, it may not be a taboo jvmpvaanr,subject but generally folks don’t talk about such subjects. To the next! All the best!!

  8. the Swedish company filed an antitrust lawsuit in Europe, claiming that Apple abused its control over the App Store and made an offer to promote Apple’s services. Apple denied the allegation.

  9. so it is entirely possible for the Fed to quickly reverse the dovish position held since the beginning of 2019. O’Neill said any signs that the Fed is tightening monetary policy will disrupt the US stock market and bond market.

  10. By comparison, relative unknown South Bend, Ind. Mayor Pete Buttigieg has shot up to third place in some recent polls after strong performances in TV interviews and on the hustings. A core source of Buttigiegs rise? Former Biden supporters.

  11. Write more, thats all I have to say. Literally, it seems as though
    you relied on the video to make your point. You obviously know what youre talking about, why throw away your intelligence on just posting videos to your site when you could be giving us something informative to read?

  12. Can I simply say what a relief to discover somebody who actually knows what they’re talking about on the
    internet. You certainly realize how to bring a problem to light and make
    it important. A lot more people need to check this out and understand
    this side of your story. It’s surprising you are not more
    popular given that you most certainly have the gift.

  13. Nolvadex For Sale Is Suhagra Otc In Canada Malegra Dxt Review [url=http://4rxday.com]cialis[/url] Como Comprar Viagra En Usa Cialis Viagra Generico Online Viagra Cialis In Farmacia

  14. 827107 911390Hello, Neat post. There is an problem along along with your website in web explorer, could test thisK IE nonetheless could be the marketplace leader and a huge portion of other people will miss your magnificent writing because of this difficulty. 760753

  15. msbzqhyzude,Thanks for ones marvelous posting! I actually enjoyed reading it, you will be a great author.I will always bookmark your blog and will htakpgpw,come back from now on. I want to encourage that you continue your great writing, have a nice afternoon!

Leave a Reply

Your email address will not be published.

Back to top button